CDK4/6 inhibitors in breast cancer

Anti-Cancer Drugs

Volumn 26, Issue 8, 2015, Pages 797-806

  Dukelow, Tim ^a   Kishan, Divya ^c   Khasraw, Mustafa ^c,d   Murphy, Conleth G ^a,b  

^a BON SECOURS HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

breast cancer; CDK4 6 inhibitors; clinical trials

Indexed keywords

ABEMACICLIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ESTROGEN; FLAVOPIRIDOL; PALBOCICLIB; RIBOCICLIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 84938817804     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000249     Document Type: Review

References (97)

1. GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr [Accessed 05 August 2014].
2. Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 2011; 103:1397-1402.
3. Udvardy A. The role of controlled proteolysis in cell-cycle regulation. Eur J Biochem 1996; 240:307-313.
4. Coudreuse D, Nurse P. Driving the cell cycle with a minimal CDK control network. Nature 2010; 468:1074-1079.
5. Hunt T, Nasmyth K, Novak B. The cell cycle Introduction. Philos Trans R Soc B-Biol Sci 2011; 366:3494-3497.
6. Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev 2001; 101:2511-2526.
7. Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med 1998; 4:1103-1106.
8. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699.
9. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12:676-684.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
11. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-330.
12. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010; 138:1920-1930.e2.
13. Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle (Georgetown, Tex) 2007; 6:667.
14. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms and genotoxic stress. Environmental Health Perspectives 1999; 107 (Suppl 1):5-24.
15. Gil J, Peters G. Regulation of the INK4b-Arf-INK4a tumor suppressor locus: all for one and one for all. Nat Rev Mol Cell Biol 2006; 7:667-677.
16. Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 2008; 7:892-898.
17. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998; 395:237-243.
18. Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16 (INK4A)and their relevance to cancer. Biochemistry 2011; 50:5566-5582.
19. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-1512.
20. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411:1017.
21. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9:23-32.
22. Malumbres M, Barbacid M. Is cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 2006; 9:2-4.
23. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999; 22:44-52.
24. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31.
25. Malumbres M, Sotillo R, Santamaría D, Galan J, Cerezo A, Ortega S. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118:493-504.
26. Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs 2014; 23:295-304.
27. Zhang L, Yang C. Promise of cyclin-dependent kinases 4/6 as therapeutic targets in breast cancer. J Carcinog Mutagen 2014; 5:191.
28. Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57:3533-3561.
29. Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 2012; 3:658-669.
30. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999; 154:113-118.
31. Musgrove EA, Lilischkis R, Cornish AL, Lee CS, Setlur V, Seshadri R, et al. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer 1995; 63:584-591.
32. Saha Roy S, Vadlamudi RK. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012; 2012:654698.
33. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M. 17betaestradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene1996; 12:2315-2324.
34. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogeninduced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclindependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997; 272:10882-10894.
35. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62:233-247.
36. Bianco S, Gévry N. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription 2012; 3:165-170.
37. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88:405-415.
38. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997; 17:5338-5347.
39. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A 1999; 96:5382-5387.
40. Casimiro MC, Wang C, Li Z, Di Sante G, Willmart NE, Addya S. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013; 27:1415-1428.
41. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77.
42. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992; 84:1736-1740.
43. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404.
44. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22:315-322.
45. Grendys EC Jr, Blessing JA, Burger R, Hoffman J. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 98:249-253.
46. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002; 62:1707-1717.
47. Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841-5846.
48. Jain SK, Bharate SB, Vishwakarma RA. Cyclin-dependent kinase inhibition by flavoalkaloids [review]. Mini Rev Med Chem 2012; 12:632-649.
49. Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother 2014; 15:407-420.
50. Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Briefing Document on LEE011 (FDA advisory committee meeting briefing documents). Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM375648.pdf. [Accessed 07 August 2014].
51. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014; 32:825-837.
52. Statement detailing approval of palbociclib. Available at http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm. [Accessed 17 March 2015].
53. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-1438.
54. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104:1862-1868.
55. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18:568-576.
56. DeMichele A, Clark AS, Heitjan D, Randolph S, Gallagher M, Lal P, et al. A phase II trial of an oral CDK4/6 inhibitor, PD0332991, in advanced breast cancer [abstract]. J Clin Oncol 2013; 31s:519.
57. Slamon DJ, Hurvitz SA, Applebaum S, Glaspy JA, Allison MK, DiCarlo BA, et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer [abstract 3060]. J Clin Oncol 2010; 28:15s.
58. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. Results of a randomized phase study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for firstline treatment of ER +/HER2-advanced breast cancer (BC). Cancer Res 2012; 72:(24 suppl):abstract nr S1-6.
59. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16:25-35.
60. Finn R, Crown J, Ettl J, Pinter T, Schmidt M, Huang-Bartlett C, et al. Clinical patterns of palbociclib associated neutropenia in the PALOMA-1/ TRIO-18 TRIAL. Annals of Oncology 2014; 25 (Suppl 4):iv116-iv136.
61. PALOMA-2 study. Available at: http://clinicaltrials.gov/ct2/show/ NCT01740427. [Accessed 01 August 2014].
62. PALOMA-3 study. Available at: http://clinicaltrials.gov/ct2/show/ NCT01942135 [Accessed 01 August 2014].
63. Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther 2013; 12:PR02.
64. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5:921-929.
65. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-3511.
66. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010; 102:1762-1768.
67. O'Brien NA, Tomaso ED, Ayala R, Tong L, Issakhanian S, Linnartz R, et al. In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014; San Diego, CA. Philadelphia, PA: AACR. Cancer Res 2014;74(19 Suppl): Abstract nr 4756.
68. Infante JR, Shapiro GI, Witteveen PO, Gerecitano JF, Ribrag V, Chugh R, et al. Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas [abstract] In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 19-23 Oct 2013; Boston, MA. Philadelphia (PA): AACR. Mol Cancer Ther 2013;12(11 Suppl): Abstract nr A276.
69. Infante JR, Shapiro GI, Witteveen PO, Gerecitano JF, Ribrag V, Chugh R, et al. Abstract 2528: a phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol 2014; 32:5s.
70. MONALEESA-2 study. Available at http://clinicaltrials.gov/ct2/show/ NCT01958021. [Accessed 01 August 2014].
71. MONALEESA-1 study. Available at http://clinicaltrials.gov/ct2/show/ NCT01919229. [Accessed 01 August 2014].
72. Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01872260. [Accessed 01 August 2014].
73. Study of LEE011 with fulvestrant and BYL719 or BKM120 in advanced breast cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT02088684. [Accessed 01 August 2014].
74. Phase 1b/2 trial of LEE011 with Everolimus (RAD001) and Exemestane in the treatment of ER + HER2-advanced breast cancer. Available at: http:// clinicaltrials.gov/ct2/show/NCT01857193. [Accessed 01 August 2014].
75. Sanchez-Martinez C, Gelbert LM, Shannon H, De Dios A, Staton BA, Ajamie RT, et al. LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts, In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR. Mol Cancer Ther 2011;10(11 Suppl): Abstract nr B234.
76. Dempsey JA, Chan EM, Burke TF, Beckmann RP. LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer [abstract], In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10;Washington, DC. Philadelphia (PA): AACR. Cancer Res 2013;73(8 Suppl): Abstract nr LB-122.
77. Shapiro G, Rosen LS, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol 2013; 31:(suppl): abstract 2500.
78. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer [abstract], In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR. Cancer Res 2014;74(19 Suppl): Abstract nr CT232.
79. MONARCH 2 study. Available at: http://clinicaltrials.gov/ct2/show/ NCT02107703. [Accessed 1 August 2014].
80. A study of LY2835219 (Abemaciclib) in combination with therapies for breast cancer that has spread. Available at: http://clinicaltrials.gov/ct2/show/ NCT02057133. [Accessed 01 August 2014].
81. Phase 1b study of PD-0332991 in combination with T-DM1 (Trastuzumab-DM1). Available at: http://clinicaltrials.gov/ct2/show/NCT01976169. [Accessed 01 August 2014].
82. Dose escalation study of LEE011 in combination with buparlisib and letrozole in HR+ , HER2-negative post-menopausal women with advanced breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT02154776. [Accessed 01 August 2014].
83. a study of oral palbociclib (PD-0332991), a CDK4/6 inhibitor, as single agent in japanese patients with advanced solid tumors or in combination with letrozole for the first-line treatment of postmenopausal japanese patients with ER (+) HER2 (-) advanced breast cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT01684215. [Accessed 01 August 2014].
84. PD 0332991 and Anastrozole for stage 2 or 3 estrogen receptor positive and HER2 negative breast cancer. Available at: http://clinicaltrials.gov/ct2/ show/NCT01723774. [Accessed 01 August 2014].
85. Letrozole and CDK 4/6 inhibitor for ER positive, HER2 negative breast cancer in postmenopausal women. Available at: http://clinicaltrials.gov/ct2/ show/NCT01709370. [Accessed 01 August 2014].
86. A study of Palbociclib in combination with adjuvant endocrine therapy for hormone receptor positive, HER2 negative invasive breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT02040857. [Accessed 01 August 2014].
87. Phase III Study of palbociclib (PD-0332991) in combination With exemestane versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL). Available at: http://clinicaltrials.gov/ct2/show/NCT02028507. [Accessed 01 August 2014].
88. A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). Available at: http://clinicaltrials. gov/ct2/show/NCT01864746. [Accessed 01 August 2014].
89. Pishvaian MJ, Yang S, El Zouhairi M, Wu CS, Mishra L, Avantaggiati M. Synergistic anti-cancer activity of the CDK4/6 inhibitor PD-0332991 in combination with 5-fluorouracilbased chemotherapy in human colon cancer cells (abstract), In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR. Cancer Res 2010; 70(8 Suppl): Abstract nr 5047.
90. McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell cycle 2012; 11:2747-2755.
91. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012; 104:476-487.
92. PD0332991/Paclitaxel in advanced breast cancer. Available at: http:// clinicaltrials.gov/ct2/show/NCT01320592. [Accessed 01 August 2014].
93. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29:4018-4032.
94. Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes & Cancer 2014; 5:261-272.
95. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010; 120:2528-2536.
96. Safety, pharmacokinetic and pharmacodynamic study of the CDK 4/6 inhibitor G1T28-1. Available at: https://www.clinicaltrials.gov/ct2/show/ NCT02243150. [Accessed 3 December 2014].
97. Cyclin dependent kinase (CDK)4/6 inhibitor, PD0332991 in advanced nonsmall cell lung cancer NSCLC. Available at: http://clinicaltrials.gov/show/ NCT01291017. [Accessed 3 December 2014].